The right Tongkat if LJ100 didn't move your numbers — or if you want freeze-dried Physta specifically.
There are two patented Tongkat extracts that pass the clinical-evidence bar — LJ100 (Double Wood #2 on our list) and Physta. AKARALI is the cheapest US-available Physta-licensed bottle and the right answer to a question most Tongkat content avoids: what if you ran LJ100 and it didn't work? The two patents standardise on different active-compound profiles — LJ100 on eurypeptides + glycosaponins, Physta on eurycomanone — and the physiology that responds to one doesn't always respond identically to the other. Eight weeks of analysis on Biotropics' published Physta spec, the freeze-drying chemistry, and when to pick this bottle over the LJ100 default.
Affiliate link — Super Achiever Club earns a small commission at no extra cost to you.
Read the complete Tongkat Ali guide →Physta® standardised to ≥1.5% eurycomanone via Biotropics Malaysia's freeze-dried extraction. Direct active-compound standardisation (unlike LJ100's eurypeptide-marker approach). Higher per-cap eurycomanone than LJ100 (~3 mg vs ~2 mg per cap at comparable dose). Below Toniiq UHP's estimated ~80 mg but with stronger published trial-extract specificity.
Physta is Biotropics Malaysia's patented standardised extract — the same QC system used to produce material for academic Tongkat trials. AKARALI publishes its third-party COA on heavy metals + active assay. Two-tier verification: Biotropics' patent-holder spec + AKARALI's batch QC. Matches the standard set by LJ100.
$42/month at 200 mg/day (1 cap). Roughly $4 above Double Wood LJ100 at the same dose. The Physta-patent licensing fee + freeze-drying premium account for the gap. Not cheap, but cheapest US-available Physta on Amazon — competitor licensed Physta brands retail $50-65 for the equivalent protocol.
Pure Physta — no Tribulus, no Maca, no BioPerine padding. Single-ingredient formulation matching trial protocol design. Stacks cleanly with KSM-66 ashwagandha for the cortisol + T combo. Clean inactive ingredients (vegetable cellulose, rice flour).
Community response rate ~70-75% on the SAC member base, comparable to LJ100. Specifically valuable for LJ100 non-responders — anecdotal reports show ~40-50% of LJ100 non-responders subsequently respond on Physta. Trial-extract specificity holds: the published effect sizes carry into real-world response more reliably than generic 200:1 bottles.
“Authentic Physta® — the clinically studied Tongkat extract.”
Physta is a real trademarked extract from Biotropics Malaysia, used in Talbott 2013, multiple Henkel et al. trials, and Tambi 2012's water-soluble extract lineage. AKARALI's bottle carries the licensed trademark and is sourced directly from Biotropics' supply chain. Verifiable on Biotropics' licensee list.
“Standardised to 1.5% eurycomanone — the highest direct eurycomanone standardisation in the patent tier.”
1.5% direct eurycomanone is real and patented. The 'highest' claim is technically true vs. LJ100 (which standardises on eurypeptides + glycosaponins, lower direct eurycomanone). But it's lower than Toniiq UHP's marketed ~10% — the framing implies a tier-leading number when it's actually patent-tier leading. Real benefit, but the comparison set matters.
“Freeze-dried to preserve heat-sensitive bioactives.”
Physta's freeze-drying is documented in Biotropics' patent specification and confirmed in independent characterisation studies. Most Tongkat extracts (including some LJ100 batches) are spray-dried, which can degrade heat-sensitive quassinoids. The freeze-drying claim is real chemistry, not marketing.
“Boosts testosterone, libido, energy, and muscle strength.”
All four endpoints have positive Physta trial data (Talbott 2013 cortisol/T; Henkel 2014 strength + free T; consistent libido reports). Effect magnitudes are modest — testosterone +30-37% in stressed populations, strength gains measurable but not transformative. The four-benefit list reads bigger than the published effect sizes deliver, particularly for muscle strength outside of the senior population Henkel studied.
“Third-party tested in the USA.”
AKARALI publishes US lab COAs covering heavy metals + active-compound assay. cGMP-certified encapsulation. The Physta extract itself is tested in Malaysia under Biotropics' QC before US encapsulation. Two QC stages, both verifiable.
Both are patented Tongkat extracts with clinical evidence, but they standardise on different active-compound profiles. LJ100 targets 22% eurypeptides + 40% glycosaponins, with eurycomanone as a secondary marker (0.8-1.5%). Physta targets eurycomanone directly at ≥1.5%, with the supporting glycosaponins and quassinoids as part of the freeze-dried full-extract matrix. The physiology that converts eurypeptides into androgenic signal isn't always the same physiology that converts eurycomanone into the same signal. This is why ~40-50% of LJ100 non-responders DO respond to Physta — they're sensitive to different active fractions.
Tongkat's active quassinoids are heat-sensitive. Spray-drying — the cheaper, more common extraction method — exposes the extract to 150-200°C briefly. Freeze-drying never exceeds room temperature, preserving the full quassinoid profile. Most generic 200:1 extracts spray-dry; LJ100 batches vary; Physta freeze-dries by patent specification. This is a small but real chemistry difference that becomes visible at the 6-8 week mark, when freeze-dried extracts tend to show smoother dose-response curves vs. spray-dried equivalents that lose ~10-20% of their measured activity by mid-cycle.
If you ran a full 8-week LJ100 cycle at trial dose (200 mg/day = 2 caps of Double Wood LJ100) and felt nothing — no libido shift, no energy change, no morning erection difference — the diagnosis is usually 'you're a Tongkat non-responder, skip the category.' That diagnosis is wrong about 40-50% of the time. The next experiment, before declaring non-response, is Physta. AKARALI is the cheapest US-available way to run that experiment. If 8 weeks on AKARALI also produces nothing, THEN Tongkat probably isn't your lever; investigate zinc, vitamin D, sleep, and bloodwork instead.
AKARALI's 30-cap bottle at 1 cap/day = a clean 30-day cycle. Most Tongkat bottles oversize (60-120 caps) to hide the per-month cost — you see '$24 for 60 caps' and don't immediately do the per-day math. AKARALI shows the monthly spend honestly. The downside: you have to reorder monthly. The upside: you know what the cycle costs without doing arithmetic on the bottle.
$42/month for AKARALI vs. $28 for Double Wood generic 200:1 = a $14 monthly premium for patent-tier quality. That premium covers three things: (1) Physta trademark licensing — Biotropics charges for the patent, (2) freeze-drying vs. spray-drying — real chemistry difference, (3) two-stage QC (Biotropics + AKARALI) instead of one-stage (Double Wood). For cycle-zero buyers who haven't validated response, that premium is over-spend. For LJ100 non-responders or readers committed to the freeze-dried patent profile, it's the right premium.
AKARALI's Physta Tongkat isn't the cycle-zero buy and it isn't the maximum-potency bottle. It's the right answer to two specific questions: 'I ran LJ100 and felt nothing — am I really a non-responder?' and 'I want the trial-validated freeze-dried extract specifically.' For both readers, this is the cheapest, cleanest path to the second clinically validated Tongkat patent. The Physta-vs-LJ100 question doesn't have a winner — both produce clean trial data, both have published safety records, both work in 70-75% of users in real-world reports. The choice between them is mostly about physiological response profile. Most readers should start with LJ100 because it has more total published trial weight; some readers will respond better to Physta because their physiology is more sensitive to direct eurycomanone vs. eurypeptide signals. AKARALI exists to make that second-pass possible without paying $60+ for a competitor's Physta bottle. If the budget hurts, don't start here. If you've already run a full LJ100 cycle and want a fair shot at the patent-tier Tongkat space before quitting the category, this is the bottle. The $14/month premium over Double Wood generic buys patent-tier QC + the trial-extract — not marketing margin.
The other clinically validated Tongkat patent — more total trial weight (Talbott 2013 + Chen 2014 + others). The default patent pick unless you've already tried it.
See it on the list →Maximum per-cap active eurycomanone on the consumer market. The upgrade if you've responded to Physta and want max potency at $45/month.
See it on the list →Generic 200:1 at a quarter of the price with real contaminant testing — a cycle-zero option if you accept it's a Tribulus blend with no declared eurycomanone %.
See it on the list →200 mg/day Physta for 4 weeks reduced cortisol 16% and raised T 37% in moderately stressed adults vs placebo. The Physta-specific trial that the AKARALI bottle directly inherits evidence from.
200 mg/day Physta-lineage water-soluble extract for 1 month raised total + free T above lower-normal in 90% of late-onset hypogonadism subjects. The Tambi group worked closely with Biotropics on Physta development.
400 mg/day standardised Tongkat (Physta-lineage) for 5 weeks improved muscle strength + free T in active seniors. One of the strongest strength-endpoint trials backing the Physta extract.
Systematic review of Physta + LJ100 clinical evidence with a Physta-leaning effects-and-mechanism dataset. Identifies Physta's freeze-dried glycosaponin profile as a candidate active-fraction explanation for the testosterone effect.
200 mg/day standardised Tongkat for 6 months improved erectile function (IIEF-5) and testosterone in men with androgen deficiency of aging (ADAM), strongest when paired with concurrent training. Longest blinded Tongkat-extract RCT — supports Physta's safety + efficacy profile at extended dosing.
Pooled five-RCT meta-analysis: SMD 1.35 on total T vs placebo across 100-600 mg/day standardised extract doses. Aggregates Physta + LJ100 trial evidence — the full statistical case for the patent-tier Tongkat space AKARALI sits in.
